Tango Therapeutics, Inc. (TNGX)
24.52
+0.64
(+2.68%)
USD |
NASDAQ |
Aug 24, 16:00
24.52
0.00 (0.00%)
After-Hours: 20:00
Tango Therapeutics Enterprise Value : 3.039B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 3.039B |
| August 20, 2026 | 2.977B |
| August 19, 2026 | 3.261B |
| August 18, 2026 | 3.302B |
| August 17, 2026 | 3.276B |
| August 14, 2026 | 3.329B |
| August 13, 2026 | 3.337B |
| August 12, 2026 | 3.325B |
| August 11, 2026 | 3.453B |
| August 10, 2026 | 3.677B |
| August 07, 2026 | 3.576B |
| August 06, 2026 | 3.901B |
| August 05, 2026 | 3.866B |
| August 04, 2026 | 3.962B |
| August 03, 2026 | 3.600B |
| July 31, 2026 | 3.595B |
| July 30, 2026 | 3.660B |
| July 29, 2026 | 3.371B |
| July 28, 2026 | 3.505B |
| July 27, 2026 | 3.517B |
| July 24, 2026 | 3.502B |
| July 23, 2026 | 3.640B |
| July 22, 2026 | 3.749B |
| July 21, 2026 | 3.904B |
| July 20, 2026 | 3.655B |
| Date | Value |
|---|---|
| July 17, 2026 | 3.827B |
| July 16, 2026 | 3.672B |
| July 15, 2026 | 4.112B |
| July 14, 2026 | 4.010B |
| July 13, 2026 | 3.793B |
| July 10, 2026 | 4.248B |
| July 09, 2026 | 4.157B |
| July 08, 2026 | 4.177B |
| July 07, 2026 | 4.090B |
| July 06, 2026 | 4.059B |
| July 02, 2026 | 3.978B |
| July 01, 2026 | 3.856B |
| June 30, 2026 | 4.282B |
| June 29, 2026 | 4.347B |
| June 26, 2026 | 4.190B |
| June 25, 2026 | 3.998B |
| June 24, 2026 | 3.851B |
| June 23, 2026 | 3.746B |
| June 22, 2026 | 3.762B |
| June 18, 2026 | 3.685B |
| June 17, 2026 | 4.308B |
| June 16, 2026 | 4.289B |
| June 15, 2026 | 4.396B |
| June 12, 2026 | 4.113B |
| June 11, 2026 | 3.952B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Revolution Medicines, Inc. | 42.13B |
| Erasca, Inc. | 5.286B |
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 12.17M |
| Summit Therapeutics, Inc. | 9.767B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.34M |
| Total Expenses (Quarterly) | 55.34M |
| EPS Diluted (Quarterly) | -0.3692 |
| Earnings Yield | -3.42% |
| Normalized Earnings Yield | -3.416 |